Clinical utility of emerging biomarkers in prostate cancer liquid ...

Liquid biomarkers have high potential to be used for prognosis, monitoring treatment response and guiding treatment selection.

In this review we focus on the clinical application of novel liquid biomarkers that have the potential to monitor and stratify patients.

Clinical utility of emerging liquid biomarkers in advanced prostate ...

The therapeutic landscape of advanced prostate cancer (PCa) has rapidly expanded in recent years. Despite significant improvements in patient overall ...

Clinical utility of emerging liquid biomarkers in advanced prostate ...

The development of molecular biomarkers will be key for patient stratification, and for monitoring response and resistance to therapy. In this context, ...

Clinical utility of emerging liquid biomarkers in advanced prostate ...

Actionable DNA repair and PI3K pathway alterations can be detected by ctDNA profiling. Abstract. The therapeutic landscape of advanced prostate cancer (PCa) has ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Schalken (2020) Clinical utility of emerging biomarkers in prostate cancer liquid biopsies,. Expert Review of Molecular Diagnostics, 20:2 ...

Clinical utility of emerging liquid biomarkers in ... - Cancer Genetics

The therapeutic landscape of advanced prostate cancer (PCa) has rapidly expanded in re- cent years. Despite significant improvements in patient overall ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Prostate specific antigen (PSA) monitoring and histopathological examination of tumor biopsies remain gold standards in PCa diagnostics. These ...

Liquid Biomarkers in Prostate Cancer Diagnosis

Emerging biomarkers, including non-coding RNAs, circulating tumor DNA, and prostate-specific antigen (PSA) glycosylation, offer valuable ...

Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in ... - MDPI

Prostate cancer (PCa) is the most common cancer in men and the second most common cause of mortality in this population in the United States, with 191,930 new ...

[PDF] Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in ...

Current knowledge about non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore, ExoDx, ...

Liquid Biomarkers in Prostate Cancer Diagnosis

Emerging diagnostic biomarkers in liquid biopsy. Recently ... Clinical utility of the prostate cancer gene. 3 (PCA3) urine assay in ...

Emerging biomarkers in the diagnosis of prostate cancer | PGPM

It is of utmost importance to identify which PCa are destined to progress and which would benefit from an early radical treatment. Prostate- ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies · List of references · Publications that cite this publication.

Current and emerging tissue‐based molecular biomarkers for ...

0.670) with respect to distinguishing clinically significant prostate cancer from low-grade disease or a negative biopsy. Similar results were ...

The promising role of new molecular biomarkers in prostate cancer

Several novel biomarkers for PCa have been proposed, however, their clinical utility remains to be discussed. Nevertheless, coding genes used as ...

Advances in Prostate Cancer Biomarkers and Probes

However, the occurrence and development of PCa is a complex biological process, and it is often challenging to meet the clinical needs only by routine rectal ...

An Improved Prostate Cancer Biomarker Test May Help Men Avoid ...

Researchers funded by NCI have developed and validated a new prostate cancer urinary biomarker test that can help differentiate who should proceed for biopsy.

Blood-based liquid biopsies for prostate cancer: clinical ... - Nature

Analysis of multiple tissue-specific methylation markers using methylation array-based approach has shown ctDNA can be prognostic of treatment ...

Clinical utility of emerging biomarkers in prostate cancer liquid ...

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Boerrigter, E.; Groen, L.N.; Van Erp, N.P.; Verhaegh, G.W.; Schalken, J.A.. Expert ...